Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 324-331

  Mei, Ling ^a   Liu, Yayuan ^a   Zhang, Qianyu ^a   Gao, Huile ^a   Zhang, Zhirong ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Combined treatment; CXCR4 antagonist; Liposomal doxorubicin; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CALCIUM; CHEMOKINE RECEPTOR CXCR4; DOXORUBICIN; LIPOSOME; MACROGOL DERIVATIVE; ONCOPROTEIN;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL ADHESION; DRUG EFFECTS; HUMAN; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; NEOPLASM METASTASIS; TUMOR CELL LINE; WOUND HEALING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM; CELL ADHESION; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; ONCOGENE PROTEIN V-AKT; POLYETHYLENE GLYCOLS; RECEPTORS, CXCR4; WOUND HEALING;

EID: 84908701504     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.10.017     Document Type: Article

References (48)

1. S. Valastyan, R.A. Weinberg, Tumor metastasis: molecular insights and evolving paradigms, Cell 147 (2) (2011) 275-292.
2. G.P. Gupta, J. Massagué, Cancer metastasis: building a framework, Cell 127 (4) (2006) 679-695.
3. R.B. Ewesuedo, M.J. Ratain, Oncologic Therapies, Springer, 2003. 19-66.
4. R. Kuai,W. Yuan, Y. Qin, H. Chen, J. Tang, M. Yuan, Z. Zhang, Q. He, Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes, Mol. Pharm. 7 (5) (2010) 1816-1826.
5. J. Tang, H. Fu, Q. Kuang, L. Zhang, Q. Zhang, Y. Liu, R. Ran, H. Gao, Z. Zhang, Q. He, Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery, J. Drug Target. (0) (2014) 1-14.
6. Y. Liu, R. Ran, J. Chen, Q. Kuang, J. Tang, L. Mei, Q. Zhang, H. Gao, Z. Zhang, Q. He, Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting, Biomaterials 35 (17) (2014) 4835-4847.
7. T.M. Allen, C.B. Hansen, D.E.L. de Menezes, Pharmacokinetics of long-circulating liposomes, Adv. Drug Deliv. Rev. 16 (2) (1995) 267-284.
8. P.S. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, Nat. Med. 12 (8) (2006) 895-904.
9. J.A. Aguirre-Ghiso, Models, mechanisms and clinical evidence for cancer dormancy, Nat. Rev. Cancer 7 (11) (2007) 834-846.
10. J.P. Thiery, H. Acloque, R.Y. Huang, M.A. Nieto, Epithelial-mesenchymal transitions in development and disease, Cell 139 (5) (2009) 871-890.
11. Y. Liang, P. Meleady, I. Cleary, S. McDonnell, L. Connolly, M. Clynes, Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and b i N in vitro invasiveness, Eur. J. Cancer 37 (8) (2001) 1041-1052.
12. T.D. Palmer, W.J. Ashby, J.D. Lewis, A. Zijlstra, Targeting tumor cell motility to prevent metastasis, Adv. Drug Deliv. Rev. 63 (8) (2011) 568-581.
13. F. Balkwill, Cancer and the chemokine network, Nat. Rev. Cancer 4 (7) (2004) 540-550.
14. J.A. Burger, T.J. Kipps, CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment, Blood 107 (5) (2006) 1761-1767.
15. I.S. Zeelenberg, L. Ruuls-Van Stalle, E. Roos, The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases, Cancer Res. 63 (13) (2003) 3833-3839.
16. C.J. Scotton, J.L. Wilson, K. Scott, G. Stamp, G.D. Wilbanks, S. Fricker, G. Bridger, F.R. Balkwill, Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer, Cancer Res. 62 (20) (2002) 5930-5938.
17. S. Scala, A. Ottaiano, P.A. Ascierto, M. Cavalli, E. Simeone, P. Giuliano, M. Napolitano, R. Franco, G. Botti, G. Castello, Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma, Clin. Cancer Res. 11 (5) (2005) 1835-1841.
18. J.A. Burger, A. Peled, CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23 (1) (2009) 43-52.
19. L. Portella, R. Vitale, S. De Luca, C.D. Alterio, C. Ieranò, M. Napolitano, A. Riccio, M.N. Polimeno, L. Monfregola, A. Barbieri, Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases, PLoS One 8 (9) (2013) e74548.
20. K. Kogawa, H. Muramatsu, M. Tanaka, Y. Nishihori, S. Hagiwara, K. Kuribayashi, K. Nakamura, K. Koike, S. Sakamaki, Y. Niitsu, Enhanced inhibition of experimental metastasis by the combination chemotherapy of Cu-Zn SOD and adriamycin, Clin. Exp. Metastasis 17 (3) (1999) 239-244.
21. A.K. Azab, J.M. Runnels, C. Pitsillides, A. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, B. Ospina, A.L. Carlson, CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy, Blood 113 (18) (2009) 4341-4351.
22. U.M. Domanska, H. Timmer-Bosscha, W.B. Nagengast, T.H.O. Munnink, R.C. Kruizinga, H.J. Ananias, N.M. Kliphuis, G. Huls, E.G. De Vries, I.J. de Jong, CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy, Neoplasia 14 (8) (2012) 709.
23. T. Zong, L. Mei, H. Gao, W. Cai, P. Zhu, K. Shi, J. Chen, Y. Wang, F. Gao, Q. He, Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals, Mol. Pharm 11 (7) (2014) 2346-2357.
24. J. Shen, H. Sun, P. Xu, Q. Yin, Z. Zhang, S. Wang, H. Yu, Y. Li, Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles, Biomaterials 34 (5) (2013) 1581-1590.
25. B.A. Teicher, S.P. Fricker, CXCL12 (SDF-1)/CXCR4 pathway in cancer, Clin. Cancer Res. 16 (11) (2010) 2927-2931.
26. J. Yao, L. Zhang, J. Zhou, H. Liu, Q. Zhang, Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and paclitaxel based on hyaluronic acid-based multifunctional nanocarrier, Mol. Pharm. 10 (3) (2013) 1080-1091.
27. D. Uchida, T. Onoue, Y. Tomizuka, N.M. Begum, Y. Miwa, H. Yoshida, M. Sato, Involvement of an autocrine stromal cell-derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma, Mol. Cancer Res. 5 (7) (2007) 685-694.
28. T. Mori, R. Doi, M. Koizumi, E. Toyoda, D. Ito, K. Kami, T. Masui, K. Fujimoto, H. Tamamura, K. Hiramatsu, CXCR4 antagonist inhibits stromal cell-derived factor 1- induced migration and invasion of human pancreatic cancer, Mol. Cancer Ther. 3 (1) (2004) 29-37.
29. T. Murakami, A.R. Cardones, S.T. Hwang, Chemokine receptors and melanoma metastasis, J. Dermatol. Sci. 36 (2) (2004) 71-78.
30. A. Müller, B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S.N. Wagner, Involvement of chemokine receptors in breast cancer metastasis, Nature 410 (6824) (2001) 50-56.
31. T. Murakami, W. Maki, A.R. Cardones, H. Fang, A.T. Kyi, F.O. Nestle, S.T. Hwang, Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells, Cancer Res. 62 (24) (2002) 7328-7334.
32. T. Sugiyama, Y. Sadzuka, Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma, Clin. Cancer Res. 5 (2) (1999) 413-416.
33. I.C. Anderson, M.A. Shipp, A.J. Docherty, B.A. Teicher, Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma, Cancer Res. 56 (4) (1996) 715-718.
34. A.A. Gabizon, Liposome circulation time and tumor targeting: implications for cancer chemotherapy, Adv. Drug Deliv. Rev. 16 (2) (1995) 285-294.
35. J. Li, Y. Zhu, S.T. Hazeldine, C. Li, D. Oupický, Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion, Angew. Chem. Int. Ed. 51 (35) (2012) 8740-8743.
36. M.B. Meads, L.A. Hazlehurst, W.S. Dalton, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance, Clin. Cancer Res. 14 (9) (2008) 2519-2526.
37. Y. Nefedova, T.H. Landowski, W.S. Dalton, Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms, Leukemia 17 (6) (2003) 1175-1182.
38. T. Hikawa, T. Mori, T. Abe, S. Hori, The ability in adhesion and invasion of drug-resistant human glioma cells, J. Exp. Clin. Cancer Res. 19 (3) (2000) 357-362.
39. G. Kouniavsky, M. Khaikin, I. Zvibel, D. Zippel, S. Brill, Z. Halpern, M. Papa, Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines, Clin. Exp. Metastasis 19 (1) (2002) 55-60.
40. T. Matsunaga, N. Takemoto, T. Sato, R. Takimoto, I. Tanaka, A. Fujimi, T. Akiyama, H. Kuroda, Y. Kawano, M. Kobune, Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acutemyelogenous leukemia, Nat. Med. 9 (9) (2003) 1158-1165.
41. L. Jin, K.J. Hope, Q. Zhai, F. Smadja-Joffe, J.E. Dick, Targeting of CD44 eradicates human acute myeloid leukemic stem cells, Nat. Med. 12 (10) (2006) 1167-1174.
42. Z. Zeng, Y.X. Shi, I.J. Samudio, R. Wang, X. Ling, O. Frolova, M. Levis, J.B. Rubin, R.R. Negrin, E.H. Estey, Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML, Blood 113 (24) (2009) 6215-6224.
43. B.D. Manning, L.C. Cantley, AKT/PKB signaling: navigating downstream, Cell 129 (7) (2007) 1261-1274.
44. T.L. Yuan, L.C. Cantley, PI3K pathway alterations in cancer: variations on a theme, Oncogene 27 (41) (2008) 5497-5510.
45. M. Bezler, J.G. Hengstler, A. Ullrich, Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells, Mol. Oncol. 6 (5) (2012) 516-529.
46. L. Liu, X. Zhou, G. Qian, X. Shi, J. Fang, B. Jiang, AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/ p70S6K1 pathway, Cancer Res. 67 (13) (2007) 6325-6332.
47. X. Li, Y. Lu, K. Liang, B. Liu, Z. Fan, Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells, Breast Cancer Res. 7 (5) (2005) R589-R597.
48. S.R. Vlahakis, A. Villasis-Keever, T. Gomez, M. Vanegas, N. Vlahakis, C.V. Paya, G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways, J. Immunol. 169 (10) (2002) 5546-5554.